Citadel Advisors
HUMA icon

Citadel Advisors’s Humacyte HUMA Stock Holding History

Citadel Advisors’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Buy
+1,443,376
New +$1.34M ﹤0.01% 7917
2026
Q1 		– Sell
-1,566,431
Closed -$1.63M – 13527
2025
Q4 		$1.5M Buy
1,566,431
+673,479
+75% +$954K ﹤0.01% 6505
2025
Q3 		$1.55M Buy
892,952
+268,194
+43% +$525K ﹤0.01% 6586
2025
Q2 		$1.31M Sell
624,758
-2,287,143
-79% -$4.39M ﹤0.01% 6524
2025
Q1 		$4.96M Buy
2,911,901
+2,740,439
+1,598% +$10.3M ﹤0.01% 3884
2024
Q4 		$866K Buy
171,462
+18,318
+12% +$90.6K ﹤0.01% 7353
2024
Q3 		$833K Buy
153,144
+109,242
+249% +$720K ﹤0.01% 7227
2024
Q2 		$211K Sell
43,902
-210,349
-83% -$1.09M ﹤0.01% 9815
2024
Q1 		$791K Buy
254,251
+69,121
+37% +$232K ﹤0.01% 7420
2023
Q4 		$526K Sell
185,130
-93,457
-34% -$240K ﹤0.01% 7986
2023
Q3 		$816K Buy
278,587
+239,498
+613% +$792K ﹤0.01% 6998
2023
Q2 		$112K Buy
+39,089
New +$141K ﹤0.01% 10758
2023
Q1 		– Sell
-510
Closed -$1.08K – 15040
2022
Q4 		$1.08K Sell
510
-168,468
-100% -$511K ﹤0.01% 14528
2022
Q3 		$551K Sell
168,978
-30,605
-15% -$117K ﹤0.01% 8244
2022
Q2 		$640K Buy
199,583
+147,415
+283% +$820K ﹤0.01% 8086
2022
Q1 		$368K Buy
52,168
+32,275
+162% +$188K ﹤0.01% 10119
2021
Q4 		$144K Buy
+19,893
New +$197K ﹤0.01% 12315

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors's HUMA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Humacyte (HUMA) in Q2 2026: 1,443,376 shares worth $1.13M. The stake represents ﹤0.01% of the portfolio and ranks #7917 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in HUMA as recently as Q4 2025.

Citadel Advisors first reported a position in HUMA in Q4 2021 and has held it in 17 quarters since. The position peaked at $4.96M in Q1 2025. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Citadel Advisors held 1,443,376 shares of Humacyte worth $1.13M as of Q2 2026.
  • Humacyte was a new Citadel Advisors position in Q2 2026.
  • Humacyte made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7917 holding.
  • Citadel Advisors first reported a position in Humacyte in Q4 2021 and has held it in 17 quarters since.
  • Citadel Advisors's Humacyte position peaked at $4.96M in Q1 2025.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.